Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Wei-Lin Jin; Ming-Zhu Jin; Yan-Yang Tu

doi:10.1016/j.trecan.2020.01.016

Organoids: A Platform Ready for Glioblastoma Precision Medicine?

Trends Cancer. 2020 Apr;6(4):265-267. doi: 10.1016/j.trecan.2020.01.016. Epub 2020 Feb 6.

Authors

Wei-Lin Jin¹, Ming-Zhu Jin², Yan-Yang Tu³

Affiliations

¹ Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China; Institute of Nano-Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai 200240, China. Electronic address: weilinjin@sjtu.edu.cn.
² Department of Gynecology and Obstetrics, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
³ Center for Translational Medicine, Affiliated Hospital of Guilin Medical University, Guilin 541004, China.

PMID: 32209439
DOI: 10.1016/j.trecan.2020.01.016

Abstract

Patient-derived organoids can recapitulate parental tumor heterogeneity. In a recent study in Cell, Jacob et al. cultivated glioblastoma organoids (GBOs) to mimic tumor heterogeneity and chimeric antigen receptor (CAR)-T cell immunotherapy, applied it for xenograft establishment and drug testing, and generated a biobank for the timely start of post-operation therapy.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Glioblastoma*
Humans
Organoids
Precision Medicine
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Receptors, Chimeric Antigen